Retatrutide is a novel triple agonist of GLP-1 (glucagon-like peptide-1), GIP (glucose-dependent insulin-stimulating peptide) and glucagon receptor. As a multi-target hypoglycemic drug, it significantly improves blood glucose control, promotes weight loss, and may bring multiple benefits to cardiovascular metabolism by simultaneously activating three enteroinsulin-stimulating receptors.
Mechanism of action:
Exert a combined effect by activating three receptors.
1.GLP-1 receptor: Enhances insulin secretion, inhibits glucagon, delays gastric emptying, and increases satiety.
2.GIP receptor: Improves insulin sensitivity and regulates energy metabolism.
3.Glucagon receptor: Promotes fat breakdown and increases energy expenditure.
Product advantages
Product Display
Analysis Report
Customer Feedback
Packaging And Transportation
